48th week of 2021 patent applcation highlights part 12 |
Patent application number | Title | Published |
20210369766 | STRUCTURAL AND FUNCTIONAL CHARACTERISTICS OF YEAST-DERIVED POLYSACCHARIDE INDUCING TREG CELL - The present invention relates to a yeast-derived polysaccharide inducing Treg cells and a use thereof and, more particularly, to a polysaccharide comprising mannan and β-glucan, an composition for immunomodulation comprising the polysaccharide as an active ingredient, a pharmaceutical composition or food comprising the polysaccharide as an active ingredient for prevention or treatment of immune disease or inflammatory disease, a method for preparation of regulatory T cells by using the polysaccharide, a cell therapeutic agent comprising the regulatory T cells prepared by the preparation method as an active ingredient, and a treatment method using same. Even at a low dose, the novel polysaccharide according to the present invention allows the production of tolerogenic antigen presenting cells through the β-glucan and mannan structure retained therein, whereby the novel polysaccharide can induce the differentiation or production of antigen-specific regulatory T cells (Treg cells) to modulate the target immune system with low adverse effects. Therefore, MGCP and the Treg cells induced by the polysaccharide are effective for preventing or treating immune disease or inflammatory disease. | 2021-12-02 |
20210369767 | Method of treating and/or preventing viral infections - A method of treating and/or preventing viral infections caused by common cold, influenza, and coronaviruses with or without symptoms is based on a fact that virus's survival time depends on the temperature and relative humidity, and an assumption based on scientific tests that a virus can be inactivated/killed or its ability to penetrate and replicate copies inside living cells can be weakened in high temperature environment by heat exposure to the virus. Creating high temperature environment in the upper respiratory and gastrointestinal (GI) tracts and preventing spread of the virus into the lower part of the respiratory tract using continuous and prolonged hot water exposure on the virus prevents development of pneumonia and expedite recovery. | 2021-12-02 |
20210369768 | METAL DI-AMINO ACID CHELATES OR METAL TRI-AMINO ACID CHELATES - The present disclosure relates to metal di-amino acid chelates and metal tri-amino acid chelates. | 2021-12-02 |
20210369769 | MANAGEMENT OF RISK OF CATION OVERLOAD AND ELECTROLYTE IMBALANCE WITH TOPICALLY APPLIED BUFFERS - Provided herein are formulations for the safe and effective topical delivery of buffering agents. The invention includes formulations and methods to balance electrolytes, overcome cation overload, and/or deliver buffers with and without counterions that can be combined in a single use formulation or alternatively in separately applied formulations. Also provided are methods of using the formulations for the treatment of a wide variety of disorders relating to electrolyte imbalance, cation overload, or related conditions. | 2021-12-02 |
20210369770 | Therapeutic Agents for Treatment of Coronavirus Infection - A therapeutic composition for treatment of coronavirus infections. The therapeutic composition contains a gold compound effective for Rheumatoid Arthritis treatment that both generates gold-S bonds at the active pockets of the main protease of the virus and suppresses the virus induced inflammations in the body. | 2021-12-02 |
20210369771 | PHARMACEUTICAL OR FOOD SUPPLEMENT FORMULATION FOR USE IN TREATING DISORDERS CAUSED BY IRON DEFICIENCY - The present invention relates to a method of treating disorders caused by iron deficiency, comprising administering to a subject in need thereof a therapeutically effective amount of a formulation comprising, as active ingredients, a composition comprising at least 40% of 5′-ribonucleotides by weight of the total weight of the composition, and an inorganic iron salt. | 2021-12-02 |
20210369772 | NUTRITION-BASED SUPPORT FOR THE BODY'S OWN WOUND HEALING PROCESSES - The use of a preparation for nutrition-based support of the body's own wound healing processes at the local and systemic level by oral intake of the preparation, which contains per gram as a basic preparation the following mixture of vitamins and nutrients:
| 2021-12-02 |
20210369773 | COMPOSITIONS AND THERAPIES USING NANODIAMONDS SUSPENDED IN A CARRIER - A composition to treat epidermal insults may have an ungraphenated detonation synthesis nanodiamonds (UDSND) and medical grade Siberian Sea Buckthorn Berry Oil (SBB) composition in a blended uniform composition with 1% hydrocortisone cream; wherein the UDSND are at 2 nm to 4 nm in initial crystal size and in the range of 0.2% to 0.5% of the UDSND-SBB composition weight and the SBB which is 99.5% to 99.8% of the UDSND-SBB composition weight; and wherein total composition ratio is in the range of about 3:1 to 10:1 hydrocortisone cream to UDSND-SBB composition. Preferably, the total composition ratio can be about 6:1 hydrocortisone cream to UDSND-SBB composition. | 2021-12-02 |
20210369774 | MICRO-RNA-155 ENHANCES THE EFFICACY OF DENDRITIC CELL VACCINE FOR CANCER - Engineered dendritic cell vaccines, and methods of forming and applying same, that may be used as effective immunotherapies for cancers. | 2021-12-02 |
20210369775 | SYSTEMS AND METHODS FOR DETERMINING THE BENEFICIAL ADMINISTRATION OF TUMOR INFILTRATING LYMPHOCYTES, AND METHODS OF USE THEREOF AND BENEFICIAL ADMINISTRATION OF TUMOR INFILTRATING LYMPHOCYTES, AND METHODS OF USE THEREOF - The invention provides systems and methods for determining and predicting the effect of providing a population of tumor infiltrating lymphocytes (TILs) on a condition associated with an entity, for example the effect of providing a population of tumor infiltrating lymphocytes (TILs) on a subject having cancer. The systems and methods rely on acquiring a computer readable analytical signature from a sample of the entity, obtaining a trained model output value for the entity by inputting the computer readable analytical signature into a tier trained model panel, and classifying the entity based upon the trained model output value with a time-to-event class in an enumerated set of time-to-event classes, each of whom is associated with a different effect of providing a population of TILs to the entity. | 2021-12-02 |
20210369776 | COMBINATIONAL TCR-T CELL THERAPY TARGETING TUMOR ANTIGENS, TGF-BETA, AND IMMUNE CHECKPOINTS - The present disclosure is directed towards genetically engineered TCR-T cells to recognize tumor antigens and simultaneously secrete a binding protein that blocks an immune checkpoint molecule and TGF-beta. These engineered T cells demonstrate stronger antitumor response and reduced T cell exhaustion. The present disclosure provides immunotherapy against HPV- or EBV-positive cancers, among others. | 2021-12-02 |
20210369777 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS - A therapeutic composition is provided. The therapeutic composition is particularly useful in the treatment of various symptoms arising from immune responses to pathogenic infections. The therapeutic compositions includes an acellular mammalian birth tissue material composition and a stem cell composition. Methods of treatment are also provided. | 2021-12-02 |
20210369778 | SYSTEM AND METHOD FOR COLD ATMOSPHERIC PLASMA BASED T CELL THERAPY - A method for using Cold Atmospheric Plasma based T cell therapy for treating cancer including treating tumor cells with cold atmospheric plasma to permeabilize the tumor cells, condensing a mammalian CRISPR plasmid vector into compact nanostructures using one of poly-L-lysine (PLL) and Star-shaped poly(ethylene glycol)-block-polyethylenimine, and transferring into the tumor cells catalytically inactive Cas9 (dCas9) containing transcriptional activators (VP64-p65-Rta) paired with single guide RNAs (sgRNAs) and plasmid DNA (CRISPRa system) to elicit immune responses by enhancing the presentation of tumor-associated antigens. | 2021-12-02 |
20210369779 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY - The present disclosure provides compositions and methods for engineered cellular compositions and methods of immunotherapy utilizing the same. Compositions of the present disclosure for immune cell regulation comprise a chimeric antigen receptor polypeptide, a T cell receptor polypeptide, and combinations thereof. | 2021-12-02 |
20210369780 | T CELL-ANTIGEN COUPLER WITH VARIOUS CONSTRUCT OPTIMIZATIONS - A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains. | 2021-12-02 |
20210369781 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY - The present invention provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to immunoresponsive cells bearing antigen receptors, which can be chimeric antigen receptors (CARs), which express introduced ligands for immunomodulatory molecules. In particular embodiments, engineered immunoresponsive cells are antigen-directed and resist immunosuppression and/or have enhances immune-activating properties. | 2021-12-02 |
20210369782 | Hematopoietic Stem Cell Engraftment - The present invention provides clinical evidence for a method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring myeloablative conditioning. | 2021-12-02 |
20210369783 | ULTRASOUND-GUIDED RETE TESTIS INJECTION/ASPIRATION DEVICE - Ultrasound-guided rete testis injection/aspiration devices and methods are described. Some methods include inserting a needle into the rete testis space of a patient and injecting a therapeutic medium through the needle into the rete testis space and seminiferous tubules of the testis. The therapeutic medium can help to treat infertility. In some examples, the method can include monitoring intra-testicular pressure of the patient. In some examples, the therapeutic medium can include stem cells. In some examples, the therapeutic medium can include gene therapy vectors. In some examples, the method can include flushing the rete testis space and seminiferous tubules with a saline solution through the needle. Exemplary devices can include a dual lumen needle, a collection tube, a dual function pump, and flexible tubing. The dual function pump can include a dual syringe pump and a vacuum pump. | 2021-12-02 |
20210369784 | IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS - Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment. | 2021-12-02 |
20210369786 | FETAL TISSUE EXTRACT, METHODS FOR PRODUCING THE EXTRACT, AND THE USE THEREOF - Provided are fetal tissue cells or a fetal tissue extract which can effectively prevent or treat bone disorders or diseases. | 2021-12-02 |
20210369787 | ADIPOCYTE MEDIATED DELIVERY OF ANTICANCER THERAPEUTICS - Disclosed are compositions and methods related to the use of adipocytes for sustained release of anti-cancer therapeutics and treatment of cancer. In one aspect, disclosed herein are engineered adipocytes comprising an anti-cancer prodrug (such as, for example, doxorubicin prodrug) and a conjugated fatty acid (such as, for example, one or more isomers of conjugated linoleic acid including, but not limited, to 9cis, 11trans, 10trans, and/or 12cis). | 2021-12-02 |
20210369788 | PRODUCTION OF CANINE PANCREATIC ISLETS FROM AN IMMATURE PANCREAS - The present invention relates to an in vitro method for preparing and producing canine pancreatic islets from immature pancreatic tissue. Such islets express, produce and secrete insulin upon glucose stimulation. The invention further encompasses canine pancreatic islets obtainable according to the present method, islet population of said islets and compositions comprising said islets. It also relates to transduced canine pancreatic islets, or tumours or cells derived thereof. The present invention also concerns the use of said canine pancreatic islets or cells derived thereof for treating a canine pancreatic disorder, such as canine diabetes, or for diagnosing canine diabetes. | 2021-12-02 |
20210369789 | COMPOSITIONS COMPRISING SMALL EXTRACELLULAR VESICLES DERIVED FROM UMBILICAL CORD BLOOD MONONUCLEAR CELLS WITH ANTI-INFLAMMATORY AND IMMUNOMODULATORY PROPERTIES AND PROCESS FOR OBTAINING THEM - The present invention relates to a process for isolating Small Extracellular Vesicles secreted by umbilical cord blood mononuclear cells (UCBMNCs) and compositions comprising said Small Extracellular Vesicles, which are useful to be applied to autoimmune diseases therapeutics or prophylactics and/or cosmetic purposes. | 2021-12-02 |
20210369790 | METHODS AND MATERIALS FOR IDENTIFYING AND TREATING MAMMALS RESPONSIVE TO OBESITY TREATMENTS - This document provides methods and materials for identifying and treating mammals responsive to obesity treatments. For example, methods and materials for assessing a mammal's gut microbiota (e.g., a human's gut microbiota) to identify that mammal (e.g., human) as being responsive to an obesity treatment are provided. Methods and materials for treating obesity by assessing a mammal's gut microbiota (e.g., a human's gut microbiota) to identify that mammal (e.g., human) as being responsive to an obesity treatment and proceeding with an obesity treatment also are provided. | 2021-12-02 |
20210369791 | TREATING OR PREVENTING RESPIRATORY INFECTION - The present disclosure relates to a method for treating or preventing a viral and/or bacterial respiratory infection in a subject, the method comprising administering to the respiratory tract of the subject an effective amount of one or more bacteria from family Pasteurellaceae. | 2021-12-02 |
20210369792 | IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF - The present disclosure provides immunomodulatory compositions comprising live | 2021-12-02 |
20210369793 | PHASCOLARCTOBACTERIUM FAECIUM FOR USE IN THE PREVENTION AND TREATMENT OF OBESITY AND ITS COMORBIDITIES - The present invention relates to the strain | 2021-12-02 |
20210369794 | Probiotic Formulations for Improving Athletic Performance - A probiotic formulation is provided including one or more bacteria, bacterial strains or bacterial species of the genus | 2021-12-02 |
20210369795 | METHODS AND COMPOSITIONS FOR IDENTIFYING AND TREATING SUBJECTS AT RISK FOR CHECKPOINT BLOCKADE THERAPY ASSOCIATED COLITIS - The present invention relates to methods and compositions for identifying subjects treated with or considered for treatment with checkpoint blockade therapeutic agents that are at higher or lower risk for developing checkpoint therapy associated colitis, by analyzing the intestinal microbiome of those subjects. It is based, at least in part, on the discovery that the abundance of certain intestinal microbiota of the phyla Bacteroidetes, including the bacteria in the families Bacteroidaceae, Rikenellaceae, and Barnesisllaceae, and/or an increase or decrease in microbial genetic pathways involved in polyamine transport and/or B vitamin biosynthesis (e.g., (riboflavin (B2), pantothenate (B5) and thiamine (B1)) are associated with the likelihood of developing checkpoint therapy associated colitis. | 2021-12-02 |
20210369796 | COMPOSITIONS AND METHODS FOR DIGESTIVE HEALTH IN AN ANIMAL - A method of improving microbiome within an animal can comprise administering to the animal a composition comprising a probiotic and | 2021-12-02 |
20210369797 | BACTERIOPHAGE TREATMENT AND REDUCTION IN INFLAMMATORY RESPONSE - The present invention relates to the treatment of bacterial infections and the reduction of inflammatory response using bacteriophage compositions. In an aspect, provided herein are methods of treating a bacterial infection characterized by inflammation in a subject, the method comprising administering to the subject a bacteriophage composition that is essentially free of impurities, wherein the composition reduces inflammation | 2021-12-02 |
20210369798 | BACTERIOPHAGE FOR TREATMENT AND PREVENTION OF BACTERIA-ASSOCIATED CANCERS - The present invention relates to a bacteriophage composition comprising one or more (suitably two or more, or three) bacteriophages that target oncogenic (tumorigenic) bacteria, and use of the same for treating or preventing cancer. | 2021-12-02 |
20210369799 | NASAL COMPOSITIONS AND METHODS - A nasal composition comprising one or more vegetable oils that possess medicinal properties for the treatment or improvement of brain/central nervous system conditions and diseases; phospholipids and optionally glycol, the composition being cannabinoids-free. | 2021-12-02 |
20210369800 | Powderized Cannabis Oil - A method for producing a powderized cannabis oil includes providing a cannabis oil; dissolving the cannabis oil in an alcohol to form a solution; mixing amylose, amylopectin, or a combination thereof into the solution; and evaporating the alcohol. | 2021-12-02 |
20210369801 | COMPOSITIONS AND METHODS FOR TREATING COVID-119 INFECTIONS - The present disclosure relates to compositions and methods for treating a subject having a COVID-19 infection. The present disclosure relates to the use of | 2021-12-02 |
20210369802 | CANNABIS PLANT FORMULATIONS AND METHODS OF DELIVERY - Disclosed are various embodiments of natural plant compositions. Particularly, the natural plant compositions may consist of plant chemicals, such as terpenes and cannabinoids, natural oils such as hemp seed oil and essential oils such as peppermint oil and lemon oil. Delivery methods for administration of the compositions include topical administration, an oral administration and a pulmonary administration. The compositions are used for a variety of reasons ranging from medicinal to recreational. | 2021-12-02 |
20210369803 | COMPOSITION CONTAINING SALVIA MILTIORRHIZA BUNGE EXTRACT AS ACTIVE INGREDIENT FOR TREATMENT OR PREVENTION OF BENIGN PROSTATIC HYPERPLASIA OR ALOPECIA - The present disclosure relates to a composition comprising a | 2021-12-02 |
20210369804 | WITHANIA SOMNIFERA COMPOSITION, METHOD OF PREPARATION AND USE THEREOF - The invention provides to an enriched | 2021-12-02 |
20210369805 | COMPOSITIONS FOR POST-EXERCISE RECOVERY AND METHODS OF MAKING AND USING THEREOF - The application provides nutraceutical compositions supporting an active life style and helps with the post-exercise recover. In one embodiment, the nutraceutical composition includes a gelling component in a sufficient amount to provide a cohesive gelled product and an active component. The active component consists of a vitamin B composition, a carbohydrate composition, an amino acid composition, an antioxidant composition, and an anti-inflammatory. | 2021-12-02 |
20210369806 | HERBAL MIXTURE FOR VIRAL DISEASE SYMPTOMS - This invention pertains to an herbal paste comprising a mixture comprising 15 to 25 parts by weight ginger root, 15 to 25 parts by weight turmeric root, 15 to 25 parts by weight garlic 15 to 25 parts by weight lime fruit, 15 to 25 parts by weight lemon fruit, 0.5 to 1.5 parts by weight bitter kola nut, 15 to 25 parts by weight natural honey and B. optionally up to 50 parts water per 100 parts of Mixture A. Also claimed is a drink from the herbal mixture and a method of using the herbal mixture for active inhalation. | 2021-12-02 |
20210369807 | BOTULINUM NEUROTOXIN-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING - The present application provides stable peptide-based Botulinum neurotoxin (BoNT) serotype A capture agents and methods of use as detection and diagnosis agents and in the treatment of diseases and disorders. The application further provides methods of manufacturing BoNT serotype A capture agents using iterative on-bead in situ click chemistry. | 2021-12-02 |
20210369808 | CHEMICAL REPROGRAMMING OF HUMAN GLIAL CELLS INTO NEURONS FOR BRAIN AND SPINAL CORD REPAIR - Provided are methods and compositions from reprogramming human glial cells into human neurons. The reprogramming is achieved using combinations of compounds that can modify signaling via Transforming growth factor beta (TGF-β), Bone morphogenetic protein (BMP), glycogen synthase kinase 3 (GSK-3), and γ-secretase/Notch pathways. The reprogramming is demonstrated using groups of three or four compounds that are chosen from the group thiazovivin, LDN193189, SB431542, TTNPB, CHIR99021, DAPT, VPA, SAG; purmorphamine. Reprogramming is demonstrated using the group of LDN193189/CHIR99021/DAPT, the group of B431542/CHIR99021/DAPT, the group of LDN193189/DAPT/SB431542, the group of LDN193189/CHIR99021/SB431542, a three drug combination of SB431542/CHIR99021/DAPT. Reprogramming using functional analogs of the compounds is also provided, as are pharmaceutical formulations that contain the drug combinations. | 2021-12-02 |
20210369809 | MEANS AND METHODS FOR TREATING COPPER-RELATED DISEASES - The present invention relates to the field of (bio-)medicine, and more particularly to the treatment of copper-related diseases. Novel means and methods for depleting (excess) copper from organs and/or the circulation are provided. Agents with a high copper binding affinity and stabilized forms thereof are provided, as well as a novel treatment regimen. The means and methods of the present invention are particularly useful for treatment of Wilson Disease, but also for treatment of other conditions. | 2021-12-02 |
20210369810 | SELF-REPLICATING CELL SELECTIVE GENE DELIVERY COMPOSITIONS, METHODS, AND USES THEREOF - Described herein are cell-selective mRNA constructs that can contain a RNA of interest and one or more miRNA targets. The cell-selective mRNA constructs described herein can be used to express an RNA of interest to a cell in a cell-selective manner. | 2021-12-02 |
20210369811 | Integrated COVID-19 Strategies - This disclosure provides for the application of a multi-disciplinary analysis of information sources to draw novel conclusions that result in new methods to diagnose, prevent or treat COVID-19. COVID-19 appears to be an extremely complex disease, encompassing three critical aspects at least: a viral infection, an immune system disorder, and a cardiovascular/pulmonary/renal disease with significant coagulation system dysregulation. This disclosure principally focuses on modes and sites of infection of the SARS COV-2 virus and the role of lectins, the lectin complement pathway, coagulation system dysfunction, related genetic polymorphisms, trypsin-like serine proteases, interferon stimulation of the innate immune system, and other factors in the disease process. Corresponding methods to address the COVID-19 pandemic are provided. | 2021-12-02 |
20210369812 | OSTEOINDUCTIVE PEPTIDES, COMPOSITIONS, IMPLANTS, AND METHODS OF USE - Osteoinductive, bone morphogenic protein receptor-binding peptides are disclosed. The peptides may be used to coat or infuse scaffolds for use as implants into bone for enhancing the growth, proliferation, and differentiation of mesenchymal stem cells and/or osteoblasts in the bone. | 2021-12-02 |
20210369813 | MODULATING RESPONSES TO CHECKPOINT INHIBITOR THERAPY - The present invention provides for a dosing schedule for the intratumoral delivery of an immunostimulatory cytokine in combination with systemic delivery of a checkpoint inhibitor. In particular, it provides delivery of a plasmid encoding the immunostimulatory cytokine, e.g., IL-12, using intratumoral electroporation, and the systemic delivery of a PD-1 antagonist. | 2021-12-02 |
20210369814 | COMPOSITIONS OF EXENDIN-4 DERIVATIVES - In one aspect, exendin-4 derivative compositions are provided. In some embodiments, unit dose forms and kits containing such compositions are also provided. In some embodiments, such compositions are useful for treatment of hyperinsulinemic hypoglycemia. | 2021-12-02 |
20210369815 | GLUCOSE RESPONSIVE INSULINS - This disclosure provides a composition containing a conjugate with a modified insulin molecule. The conjugate has an insulin molecule, which can be insulin or an insulin analog, glucagon, GLP-1, GLP-2 or a GLP-1 agonist. The conjugate also contains one or more polymers. Each of the one or more polymers is covalently linked to the insulin molecule. Additionally, each of the one or more polymers is covalently linked to between 0 to 50 copies of a decoy ligand, and to between 0 to 50 copies of a glucose-binding agent, such that the combined total number of glucose-binding agents and decoy ligands covalently linked to each of the one or more polymers is at least 1. The conjugate can reversibly bind to soluble glucose and in which the extent of its glucose-binding controls the extent to which the modified insulin is able to bind to and activate the insulin receptor. Methods of making the conjugate, as well as use of the conjugate in treatment, are also provided. | 2021-12-02 |
20210369816 | FORMULATIONS OF ABALOPARATIDE, TRANSDERMAL PATCHES THEREOF, AND USES THEREOF - Disclosed are abaloparatide formulations for transdermal delivery of a therapeutically effective amount of abaloparatide, as well as transdermal patches prepared using these formulations, methods of preparing the disclosed formulations and patches, and methods of using these formulations and patches to treat osteoporosis, osteopenia, osteoarthritis, and/or bone fracture, improve bone mineral density (BMD), improve trabecular bone score (TBS), and treat, prevent, and/or reduce bone fractures. | 2021-12-02 |
20210369817 | CONJUGATES OF A FACTOR VIII MOIETY HAVING AN OXIME-CONTAINING LINKAGE - The present disclosure provides conjugates comprising a Factor VIII moiety covalently attached via an oxime-containing linkage to a water-soluble polymer, such as for example, a polyethylene glycol polymer. Methods for preparing and for administering such conjugates, are also provided, as are water-soluble polymer oxyamine reagents useful for preparing the subject conjugates, among other things. | 2021-12-02 |
20210369818 | HUMAN DNASE FOR LUNG DISEASE - Provided herein are pharmaceutical compositions for treating human lung diseases comprising a stabilized DNase I polypeptide containing a non-standard amino acid, a functional fragment thereof, or a variant thereof that maintains enzymatic activity even under harsh conditions, such as reducing environments. The present disclosure also relates to methods of using the composition for the treatment of human of lung diseases or for the disruption of biofilms. | 2021-12-02 |
20210369819 | HYALURONIDASE FOR THE PREVENTION, TREATMENT, REDUCTION AND/OR ABOLISHMENT OF CEREBRAL EDEMA AND INTRACRANIAL PRESSURE - The current invention is a method of treating, preventing, reducing and/or abolishing edema and/or intracranial pressure in a subject by the administration of hyaluronidase. The edema in the brain and intracranial pressure can be the result of a traumatic event, disease or condition including but not limited to a traumatic brain injury, a stroke, a brain tumor, and post-operative swelling. | 2021-12-02 |
20210369820 | METHOD FOR PROPHYLAXIS AND/OR TREATMENT OF ErbB2 POSITIVE CANCERS - Provided are compositions and methods for prophylaxis and/or therapy of ErbB2-positive cancer. The compositions include pharmaceutical preparations that contain isolated or recombinant or modified peptidase D (PEPD) proteins. The methods include prophylaxis and/or therapy of ErbB2-positive cancer by administering a PEPD to an individual who has or is at risk for developing ErbB2-positive cancer. | 2021-12-02 |
20210369821 | NON-PROTEIN CLOSTRIDIAL TOXIN COMPOSITIONS - Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions comprise a surfactant selected from a poloxamer and a polysorbate; an antioxidant selected from methionine, N-acetyl cysteine, ethylenediaminetetraacetic acid and combinations thereof, and, optionally, a tonicity agent and/or a lyoprotector selected from, for example, trehalose, sucrose. | 2021-12-02 |
20210369822 | METHODS FOR TREATMENT OF DISEASES - We describe peptides and their uses for the treatment of , e.g. acute myocardial infarction and other cytokine storm-associated conditions. | 2021-12-02 |
20210369823 | COMPOSITIONS AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM INJURY - The present invention describes compositions and method for improving outcomes after injury to the central nervous system wherein complement signaling is activated. In one aspect, the method comprises administering to a subject a therapeutically effective amount of a therapeutic agent comprising a targeted inhibitor molecule comprising a targeting portion and an inhibitor portion, wherein the molecule inhibits complement, and wherein therapeutic agent is administered in combination with rehabilitation therapy or thrombolytic agent. | 2021-12-02 |
20210369824 | METHODS AND MATERIALS FOR TREATING CANCER - This document provides methods and materials related to treating cancer. For example, methods and materials for using nucleic acid libraries to treat cancer are provided. | 2021-12-02 |
20210369825 | CD40 AND CD40L COMBO IN AN ADV VACCINE VEHICLE - A cancer vaccine is provided including a recombinant nucleic acid encoding a self-activating chimeric signaling protein, and especially chimeric TNF family ligand-receptor proteins, and a tumor-associated antigen. In a preferred embodiment, the cancer vaccine may further include a nucleic acid segment encoding an IL-15 superagonist. In addition, the cancer vaccine can be co-administered with a genetically modified bacteria or yeast as an adjuvant to increase the payload expression of the cancer vaccine. Advantageously, cells expressing such combination of molecules will enhance immune reaction against tumor cells. Compositions and methods are presented that allow for an enhanced immune response against a vaccine composition, and particularly a recombinant adenoviral expression system that is used as a therapeutic agent. Most preferably, immune therapeutics are administered such that a protein or nucleotide are co-located with a therapeutic antigen, preferably via co-expression of the protein. | 2021-12-02 |
20210369826 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 2021-12-02 |
20210369827 | COMBINATION OF VACCINATION AND OX40 AGONISTS - The present invention relates to a vaccine/agonist combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one OX40 agonist. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/agonist combination. Additionally the present invention relates to medical use of such a vaccine/agonist combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/agonist combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with an OX40 agonist. | 2021-12-02 |
20210369828 | PLANT VIRUS BASED CANCER ANTIGEN VACCINE - A vaccine composition includes an icosahedral-shaped plant virus or virus-like particle linked to a plurality of NY-ESO-1 antigens. | 2021-12-02 |
20210369829 | METHOD FOR PREPARING LIVE ATTENUATED VACCINE BY IRRADIATION AND LIVE ATTENUATED VACCINE COMPOSITION PREPARED BY THE SAME - The present invention relates to a method of preparing a live attenuated vaccine by irradiation and a live attenuated vaccine composition prepared by the same, and more particularly, a method of preparing a live attenuated vaccine by irradiation including irradiating a pathogenic microorganism with a dose of 0.5 to 2 kGy of radiation per single radiation six to fifteen times; and a live attenuated vaccine composition including a pathogenic microorganism attenuated to not be revertant to a wild type by generation of at least one mutation of nucleotide insertion and nucleotide deletion by irradiation. | 2021-12-02 |
20210369830 | CLOSTRIDIUM DIFFICILE ANTIGENS - The present application relates to recombinant | 2021-12-02 |
20210369831 | CLOSTRIDIUM DIFFICILE MULTI-COMPONENT VACCINE - Immunogenic compositions for combating | 2021-12-02 |
20210369832 | VACCINE FOR PROTECTION AGAINST STREPTOCOCCUS SUIS - The present invention pertains to a vaccine comprising an IgM protease antigen of | 2021-12-02 |
20210369833 | BACTERIAL POLYSACCHARIDE-CONJUGATED CARRIER PROTEINS AND USE THEREOF - Immunogenic compositions that include a bacterial capsular polysaccharide conjugated to a carrier protein are described. In some embodiments, the bacterial capsular polysaccharide is a | 2021-12-02 |
20210369834 | Application of Heptoglycan-chain-containing Oligosaccharide Compounds in Preparation of Vaccine against Helicobacter pylori - Disclosed is the application of heptoglycan-chain-containing oligosaccharide compounds in preparation of a vaccine against | 2021-12-02 |
20210369835 | Method of Vaccination for SARS Virus - A method of vaccination for severe acute respiratory syndrome (SARS) disease caused by at least one of SARS-CoV-1 virus and SARS-CoV-2 virus is achieved in inoculating a human with a specific vaccine composition. The vaccine composition includes a solution of salt water (H | 2021-12-02 |
20210369836 | SURFACE DISPLAY OF PROTEINS ON RECOMBINANT BACTERIA AND USES THEREOF - Recombinant microorganisms, pharmaceutical compositions thereof, and methods of protein display on the cell surface of the microorganisms are disclosed. | 2021-12-02 |
20210369837 | METHODS OF TREATING TIM-3 ELEVATION - The present disclosure provides formulations and therapies for treating subjects with elevated levels of TIM-3 using gene-based cytotoxic immunostimulant therapy alone or with other immunotherapies. | 2021-12-02 |
20210369838 | METHODS OF USING HSV-2 SINGLE CYCLE VIRUS DELTA-GD AND HSV-2 RECOMBINANT GLYCOPROTEIN D - Methods of vaccinating, immunizing and/or treating a subject against a herpes simplex virus infection or a disease caused by a herpes simplex virus infection comprise administering to the subject an effective amount of a HSV-2 single-cycle virus and an effective amount of a recombinant HSV-2 glycoprotein D, wherein the HSV-2 single-cycle virus comprises HSV-2 having a deletion of glycoprotein D-encoding gene in the genome and the HSV-2 is phenotypically complemented with an HSV-1 glycoprotein D on a lipid bilayer of the HSV-2. | 2021-12-02 |
20210369839 | MICRONEEDLE SYSTEM FOR APPLYING A HEPATITIS VACCINE - The present invention relates to a microneedle system (MNS for short) for the intradermal application of a hepatitis vaccine, namely the antigen HBsAg. | 2021-12-02 |
20210369840 | METHODS OF USE & COMPOSITIONS OF IBD, IBS, & ANTINEOPLASTIC MICROBIAL THERAPEUTICS - This invention relates to the medical use of pathogen associated molecular pattern (PAMP) displaying immunostimulatory microbial immuno-adjuvants [MIAs], as therapeutics when used in combination with check point inhibitors to treat various types of cancer and to methods of treatment which involve treating a subject with these compounds and compound mixtures and process methods for identifying and optimally composing them for their therapeutic use in cancer treatment. It also relates to the use of inhibitors of these PAMP displaying immunostimulatory microbial immuno-adjuvants [MIAs], as therapeutics when used to treat inflammatory bowel disease (IBD) including Crohn's Disease and ulcerative colitis and irritable bowel syndrome (IBS) and process methods for identifying and optimally composing them for their therapeutic use in IBD and IBS. | 2021-12-02 |
20210369841 | ANTI-RSPO3 ANTIBODIES AND METHODS OF USE - Provided herein are anti-RSPO3 antibodies and methods of using the same. | 2021-12-02 |
20210369842 | ANTIBODY FORMULATION - The present invention relates to pharmaceutical formulations of binding agents and their use in medicine. In particular, the invention relates to pharmaceutical formulations of binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the pharmaceutical formulations of the invention and to methods for producing pharmaceutical formulations. | 2021-12-02 |
20210369843 | METHODS OF TREATING TUMORS WITH PRO DRUGS - Methods of treating tumors by administering compounds to a patient are provided. Compounds such as pro drugs, e.g., 5-aminolevulinic acid (5-ALA), may be administered to the patient orally, by injection, intravenously, or topically, which then accumulate preferentially as compounds such as protoporphyrin IX (PpIX) in tumor cells. After such accumulation, compounds such as PpIX are then activated in various aspects to treat tumors cells, thereby treating cancer. Cancers such as glioblastoma may be treated. | 2021-12-02 |
20210369844 | ANTIMICROBIAL APPARATUS COMPRISING FIELD-ELECTRIC NANOPARTICLES (FENPS) AND METHOD THEREOF - The present invention provides an apparatus for targeting and disrupting, deactivating or destroying microorganisms (e.g. viruses, bacteria, fungus or diseased cells). The apparatus includes Field-Electric Nano-Particles coated, conjugated or functionalized with one or more guiding agents such as antibodies or proteins that target a type of bacteria, fungus, virus or diseased cells; a delivery module to deliver such nanoparticles into a subject's body, and an external energy field generation module. The nanoparticles, when subject to the applied external energy field, generate an electric field or pulses of electric field localized to the targeted bacteria, fungus or virus to disrupt, deactivate or destroy the targeted bacteria, fungus, viruses, or diseased cells. | 2021-12-02 |
20210369845 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T | 2021-12-02 |
20210369846 | New Ammonium Salts Of Fluorinated Organic Acids, Method Of Their Synthesis and Application - The exemplary arrangements relate to ammonium salts of partially fluorinated organic acids. The exemplary arrangements also relate to methods of synthesis of the ammonium salts of partially fluorinated organic acids. The exemplary arrangements also relate to methods of use of the ammonium salts of partially fluorinated organic acids to produce stabilizing emulsions of the oil-in-water and/or water-in-oil type. The exemplary arrangements also relate to methods of use and applications of the ammonium salts of partially fluorinated organic acids, for example use as stabilizing agents in blood substitute preparations. | 2021-12-02 |
20210369847 | METHOD FOR BOWEL PREPARATION - The present invention provides methods for facilitating cleansing of the gastrointestinal tract of a patient prior to a diagnostic, surgical or therapeutic procedure. The methods can improve patient compliance, and thus, efficacy of the preparation. Specifically, the present methods make the gastrointestinal tract preparation composition palatable for the patient to consume. For example, for a patient preparing to undergo colonoscopy, the present methods make the bowel preparation solution taste significantly less salty. | 2021-12-02 |
20210369848 | Conjugation Method for Carrier-Linked Prodrugs - The present invention relates to reagents comprising a substituted acyl borate or a substituted hydroxylamine, to a method of synthesizing a carrier-linked prodrug using said reagents and to carrier-linked prodrugs obtainable by said method. | 2021-12-02 |
20210369849 | BONE TARGETED ANTIMICROBIAL OXAZOLIDINONE RELATED COMPOUNDS, FORMULATIONS THEREOF, AND USES THEREOF - Described herein are bisphosphonate oxazolidinone compounds, and conjugates and pharmaceutical formulations thereof, that can include a bisphosphonate and an oxazolidinone (or an oxazolidinone antimicrobial or antibiotic agent, substituent or derivative thereof), where the oxazolidinone can be releasably coupled to the bisphosphonate. Also provided herein are methods of making and methods of using the bisphosphonate oxazolidinone compounds, conjugates and pharmaceutical formulations thereof. Also provided herein are methods of use of the compounds, conjugates and formulations for treating a bone disease or for use in preparing a formulation for the treatment a bone disease. | 2021-12-02 |
20210369850 | COMPOUNDS AND THERAPEUTIC USES THEREOF - The invention relates to novel compounds with the ability to link an immune response to a defined therapeutic target, to the use of said compounds in treating cancer and a disease or disorder mediated and/or caused by an infective agent, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process. | 2021-12-02 |
20210369851 | MODIFIED GLOBIN PROTEINS - Certain aspects of the present invention relate to modified proteins e.g. oxygen-carrying proteins, comprising at least one modification for homogenous conjugation of one or more polymeric moieties e.g. polyethylene glycol or derivatives thereof. | 2021-12-02 |
20210369852 | METHOD FOR IMPROVING SUBSTITUTION RATE AND/OR SUBSTITUTION EFFICIENCY OF HYALURONAN-DRUG CONJUGATES - Disclosed herein is a method for preparing a hyaluronan-drug conjugate. The method uses the ethyl cyano(hydroxyimino)acetate/diisopropylcarbodiimide coupling system in a homogeneous reaction phase, which unexpectedly improves the substitution rate and substitution efficiency of hyaluronan-drug conjugates for various drugs. | 2021-12-02 |
20210369853 | TARGETED PROTEASE DEGRADATION PLATFORM - Disclosed is a targeted protease degradation platform (TED), which in particular is a conjugate of target molecule-linker-E3 ligase ligand as shown in the structure of A-L1-B (formula I), wherein the A is the monovalent group of the target molecule, the B is the monovalent group of the E3 ligase ligand, the L1 is the linker linking A and B, and L1 is as shown in —X-L2-Y— (formula II). | 2021-12-02 |
20210369854 | COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD5+ CELLS - The invention provides anti-CD5 antibodies, antigen-binding fragments thereof, and antibody drug conjugates thereof, for use in treating, for example, a stem cell disorder, cancer, or autoimmune disease, among other hematological and proliferative diseases. Compositions and methods for depleting populations of CD5+ cells, such as CD5+ cancer cells and CD5+ immune cells are described, and can be used to treat cancers and autoimmune diseases directly as stand-alone therapies by eradicating cancerous cells and autoreactive immune cells that express CD5 and/or to prepare a patient for hematopoietic stem cell transplantation, for instance, by depleting populations of CD5+ immune cells that cross-react with, and mount an immune response against, non-self hematopoietic stem cells. | 2021-12-02 |
20210369855 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE - A conjugation of a cytotoxic drug to a cell-binding molecule with a bis-linker (dual-linker) as shown in Formula (I). Bis-linkage methods of making a conjugate of a cytotoxic drug/molecule to a cell-binding agent in a specific manner are also described, as well as application of the conjugates for the treatment of a cancer, or an autoimmune disease, or an infectious disease. | 2021-12-02 |
20210369856 | COMPOUND FOR THE SEQUESTRATION OF UNDESIRABLE ANTIBODIES IN A PATIENT - The present invention provides a compound for the sequestration of undesirable antibodies (e.g. related to an autoimmune disease) in a patient. The compound comprises an inert biopolymer scaffold and at least a first peptide n-mer of the general formula P(-S-P) | 2021-12-02 |
20210369857 | IL2 AND TNF MUTANT IMMUNOCONJUGATES - The present application relates to conjugates comprising interleukin 2 (IL2), and a mutant of tumour necrosis factor, such as tumour necrosis factor alpha (TNFα), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) or Extra-Domain B (EDB) of fibronectin. The conjugate may be used in the treatment of cancer. | 2021-12-02 |
20210369858 | USE OF EXOSOMES FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS - Provided herein are methods of using exosomes that function like minicells to deliver therapeutic agents to diseased or disordered cells. In particular, the exosomes can be targeted to particular areas of the body using growth factor gradients. These gradients also serve to trigger expression of proteins inside the exosomes, from transfected nucleic acids, at the desired target. | 2021-12-02 |
20210369859 | NANOLIPOSOME-MICROBUBBLE CONJUGATE HAVING COMPLEX OF CAS9 PROTEIN, GUIDE RNA INHIBITING SRD5A2 GENE EXPRESSION AND CATIONIC POLYMER ENCAPSULATED IN NANOLIPOSOME AND COMPOSITION FOR AMELIORATING OR TREATING HAIR LOSS CONTAINING THE SAME - The present invention relates to a nanoliposome-microbubble conjugate, in which a complex of a Cas9 protein, a guide RNA inhibiting SRD5A2 gene expression and a cationic polymer is encapsulated in a nanoliposome, and to a composition for the amelioration or treatment of hair loss containing the same. Currently, drugs used for the treatment of hair loss cause serious side effects such as loss of libido or erectile dysfunction, and hair loss progresses again when drug treatment is stopped. However, when the nanoliposome-microbubble conjugate of the present invention is used, the expression of SRD5A2 inducing hair loss can be fundamentally suppressed, and the treatment of male hair loss can be performed very effectively. | 2021-12-02 |
20210369860 | FUNCTIONALIZED NANOPARTICLE FORMULATIONS FOR ORAL DRUG DELIVERY - Drug delivery systems comprising binding partners conjugated to a nanoparticle encapsulating a therapeutic agent formulated for oral administration, and methods of delivering therapeutic agents across the gastrointestinal epithelium. | 2021-12-02 |
20210369861 | Carrier-Free Curcumin Nanoparticle for EGFR Positive Cancer Therapy - A carrier-free nanoparticle based on the self-assembly of curcumin-erlotinib conjugate (EPC) that exhibits stronger cell killing, better anti-migration effects, and anti-invasion effects for pancreatic cancer cells than the combination of free curcumin and erlotinib. | 2021-12-02 |
20210369862 | THERAPEUTIC NANOPARTICLES AND METHODS OF USE THEREOF - The present invention relates to a method and composition for optimized intracellular delivery of nucleic acids, in particular mRNA. In addition to mRNA, the composition, in particular a nanoparticle, may include a glycolipid antigen. Combinations with checkpoint inhibitors are also provided. The method and composition of the invention targets antigen presenting cells and is especially useful for immunotherapy and vaccination purposes. | 2021-12-02 |
20210369863 | METHOD OF DELIVERING GENES AND DRUGS TO A POSTERIOR SEGMENT OF AN EYE - A multifunctional dendrimer nanoparticle and method of treating diseases of the posterior segment of the eye is presented. The functionalized polyamidoamine (PAMAM) dendrimer effectively delivers drugs and/or genes to the posterior eye, thereby providing for the effective, non-invasive, and topical treatment of diseased in the posterior eye. The multifunctional dendrimer nanoparticle has shRNA-encoding DNA and small molecule drug encapsulated cyclodextrin complexed to the outer surface of the dendrimer for delivery to the posterior segment of the eye. | 2021-12-02 |
20210369864 | Vivo Radical-Mediated Polymerization for Targeted Delivery of Trophic Factors - The present invention provides a biocompatible conjugate for treating a disease or an injury. The conjugate contains a polymer covalently linked to one or more moieties each containing a polymerizable functional group. The conjugate forms a cross-linked polymer network after being exposed to an elevated level of free radicals associated with the disease or injury. | 2021-12-02 |
20210369865 | Exosomes Comprising RNA Therapeutics - The present invention pertains to extracellular vesicle (EV) therapeutics, wherein the EVs comprise nucleic acid (NA)-based therapeutics such as mRNAs, circular RNAs, miRNAs, shRNAs, circular RNA and/or DNA molecules. The NA therapeutics are loaded into EVs using inventive engineering protein and NA engineering strategies to enhance loading into EVs and to facilitate release of the NA cargo molecules inside target cells. | 2021-12-02 |
20210369866 | BIODEGRADABLE LIPIDS FOR DELIVERY OF NUCLEIC ACIDS - The present invention provides, in part, a biodegradable compound of formula I, and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof, where each X independently is O or S, each Y independently is O or S, and each R | 2021-12-02 |